Latest News and Press Releases

BENSHEIM, Deutschland, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Die erste vollständig von der EU finanzierte Psilocibin-Therapiestudie, hat nun die Zulassung der Europäischen Arzneimittel-Behörde EMA...

Avextra Portugal launches an innovative in-house breeding program to develop proprietary cannabis varieties with specific, consistent and reproducible cannabinoid and terpene profiles.Over a two-year...

The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral...

L'Agenzia Italiana del Farmaco (AIFA) e il Ministero della Salute hanno approvato ufficialmente NEUROBIS: uno studio multicentrico di Fase II per valutare la sicurezza e l'efficacia di una...

Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines, is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...

Avextra, der führende europäische vertikal integrierte Hersteller und Entwickler von Medikamenten auf Cannabisbasis, erweitert nach Abschluss seiner Finanzierungsrunde im ersten Quartal 2024 seine...

Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines is expanding its pharmaceutical development capabilities. Behind SynQube GmbH are the two...

Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors

German Pain Association (DGS) and Pharmaceutical Company Avextra Join Forces to Launch Their New Study OCEAN

Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the...